Sabater‐Abad J, Matellanes‐Palacios M, Bou‐Boluda L, et al. - In this bicentric retrospective study, researchers tested the safety and effectiveness of adalimumab 80 mg in the treatment of psoriasis. For this investigation, they retrospectively analyzed 11 individuals with psoriasis who have received treatment with the presentation of 80 mg of ADA in two dermatology departments of two hospitals in Spain since its commercialization until June 2019. An improvement in the mean final Psoriasis Area Severity Index of all patients was found at the end of the study, with no adverse effects reported by any patient. This research highlights the effectiveness and safety of 80 mg of ADA in a sample of 11 psoriasis patients.